This panel of leading industry experts will discuss key considerations and experiences related to the Make vs. Buy decision from a variety of perspectives. Speakers will debate whether those considerations are unique to today’s environment and how they might be different in the future. How have the supply chain disruptions post-pandemic affected production? Has prioritization of vaccine manufacturing been a benefit or a challenge to other therapeutic production? What is the impact of de-risking innovative technologies to improve biologics manufacturing in the future? This session will solicit significant audience input to shape the discussion.